ANNAPOLIS, Md., Sept. 16 /PRNewswire-FirstCall/ -- PharmAthene, Inc.,
(Amex: PIP) a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that David P. Wright,
President and Chief Executive Officer of PharmAthene, will present at the
UBS Global Life Sciences Conference on September 25, 2008 at 1:30 p.m. in
Ballroom E at The Grant Hyatt hotel in New York.
PharmAthene's presentation will be available via webcast on the
company's website at http://www.PharmAthene.com. A link to access the
webcast will be accessible from the Investor Relations section of the
website under News & Events / Presentations. For assistance, contact Stacey
Jurchison at 410-269-2610.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States
and its allies by developing and commercializing medical countermeasures
against biological and chemical weapons. PharmAthene's lead product
development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)
anthrax vaccine
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve
agents
-- RypVax(TM) - a recombinant dual antigen vaccine for plague
For more information about PharmAthene, please visit
http://www.PharmAthene.com.
SOURCE PharmAthene, Inc.
 back to top
Related links:
http://www.pharmathene.com
CONTACT:
Stacey Jurchison, Director, Corporate
Communications, of PharmAthene, Inc., +1-410-269-2610,
JurchisonS@PharmAthene.com
|
